acetylcysteine
acetylcysteine: 9 clinical trials tracked.
acetylcysteine evidence translation
What we can confirm
9 tracked trials
What it means
What to watch
Prepared research question
What is verified about acetylcysteine, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence6 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Clinical Trial Registry Records (9)
A Randomised Platform Trial to Evaluate Therapeutics in Patients With Moderate or Severe Dengue (DEN-HOST)
Primary endpoint: Progression to severe dengue/critical dengue
A Prospective, Open-label Phase 0 Single-center Study to Assess the Effect of Acetadote on Metabolism in Newly Diagnosed Glioblastoma
Primary endpoint: To determine the effect of Acetadote on glioblastoma metabolism as measured by MRS.
The Role of N-Acetylcysteine Inhalation in Critically Ill Mechanically Ventilated Patients
Primary endpoint: The primary endpoint of interest is incidence and time to develop ventilator associated pneumonia.
A Phase II, Single-center, Randomized Double Blind, Placebo Controlled Study to Evaluate the Effect of the Combined Therapy of EH-301 and N-acetylcysteine Together With Riluzole in Ambulant Patients Diagnosed With Amyotrophic Lateral Sclerosis (ALS)
Primary endpoint: ALSFRS-R scale
The Possible Protective Role of N-Acetylcysteine Against Oxaliplatin-Induced Peripheral Neuropathy in Patients With Colorectal Cancer
Primary endpoint: NCI-CTCAE, Version 5, 2017
Randomized Placebo Controlled Trial of Intravenous N-Acetylcysteine for the Treatment of Acute Ischemic Stroke
Primary endpoint: National Institutes of Health Stroke Scale (NIHSS)
Randomized Controlled Trial of N-acetyl Cysteine as a Neuroprotective Agent in Progressive Multiple Sclerosis
Primary endpoint: Safety and tolerability
Antioxidant Therapy With N-acetylcysteine for Motor Behavior and/or Learning in Children With Neurofibromatosis Type 1
Primary endpoint: Change From Baseline in Motor Function Measured by Physical and Neurological Examination for Soft Signs (PANESS)
Role of Oxidative Stress and Inflammation in Type 1 Gaucher Disease (GD1): Potential Use of Antioxidant/Anti-inflammatory Medications
Primary endpoint: Change in subjects with Gaucher disease type 1, in concentration of glutathione in brain (μmol/g)